DSGN
Design Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$15.14
+0.73%Aug 3, 2026, 00:00 UTC
Design Therapeutics, Inc. reported a net loss of $20.2 million for Q2 2026, with research and development expenses of $16.4 million and general and administrative expenses of $5.8 million.
Jun 30, 2026, 12:00 UTC
Design Therapeutics initiated patient dosing in a Phase 1 multiple-ascending dose trial of DT-818 for myotonic dystrophy type-1.
Source: